Comprehensive medication guide to Briviact including estimated pricing, availability information, side effects, and how to find it in stock at your local pharmacy.
Estimated Insurance Pricing
$10 copay with UCB savings card (commercial insurance); otherwise Tier 3 at $50–$150/month, prior authorization and step therapy through Levetiracetam typically required.
Estimated Cash Pricing
$1,500–$2,000/month for brand tablets; generic oral solution emerging, generic tablets anticipated at $200–$600/month when available.
Medfinder Findability Score
55/100
Summarize with AI
On this page
Briviact (Brivaracetam) is a prescription anticonvulsant medication manufactured by UCB, Inc. It is FDA-approved as adjunctive therapy for partial-onset (focal) seizures in patients 1 month of age and older. This means Briviact is used alongside other seizure medications to help reduce the frequency of focal seizures.
Briviact is a racetam derivative and a chemical analog of Levetiracetam (Keppra), but it binds to its target — synaptic vesicle glycoprotein 2A (SV2A) — with significantly higher affinity. Many patients who experience behavioral side effects on Levetiracetam find Briviact to be better tolerated.
We have a 99% success rate finding medications, even during nationwide shortages.
Need this medication?
Briviact works by selectively binding to synaptic vesicle glycoprotein 2A (SV2A) in the brain. SV2A is a protein found on the surface of synaptic vesicles — the tiny packets that store and release neurotransmitters. By binding to SV2A, Briviact modulates neurotransmitter release and reduces neuronal hyperexcitability, which is the underlying driver of seizures.
Briviact has approximately 15–30 times higher affinity for SV2A compared to Levetiracetam, which may contribute to its improved tolerability profile, particularly regarding mood and behavioral side effects. Briviact can be taken with or without food and reaches peak blood levels quickly — within about 1 hour.
Tablets
10 mg, 25 mg, 50 mg, 75 mg, 100 mg
Oral solution — solution
10 mg/mL
Intravenous injection — injection
10 mg/mL (50 mg per 5 mL vial) — used in hospitals when oral administration is temporarily not feasible
Briviact (Brivaracetam) scores a 55 out of 100 on our findability scale — meaning it can be moderately difficult to locate at your local pharmacy. While there is no formal FDA drug shortage, Briviact is a Schedule V controlled substance and a specialty anticonvulsant that many pharmacies do not routinely stock. Its relatively high cost and niche use for epilepsy mean some pharmacies only order it on request.
A generic brivaracetam oral solution (by Lupin) was approved in February 2026, which should gradually improve availability. However, generic tablets are not yet widely available. If your pharmacy doesn't have Briviact on the shelf, ask them to order it — most can get it within 1–2 business days. You can also use Medfinder to locate pharmacies near you that have it in stock right now.
Briviact is most commonly prescribed by:
Because Briviact is a Schedule V controlled substance, any licensed prescriber with DEA authorization can write a prescription. Telehealth options are available for follow-up visits and prescription renewals.
Yes, Briviact is classified as a Schedule V controlled substance by the DEA. Schedule V is the lowest level of federal control, indicating a low potential for abuse relative to Schedule IV drugs. This classification is primarily due to its structural similarity to other racetam compounds.
In practice, the Schedule V classification means your pharmacy may need to order Briviact specifically rather than keeping it on the shelf, and there may be minor additional paperwork involved. However, refill restrictions are minimal compared to higher-schedule medications.
Serious side effects (seek medical attention):
Know what you need? Skip the search.
Levetiracetam (Keppra)
Same drug class (SV2A ligand), widely available as a generic, and much cheaper at $15–$50/month. However, some patients experience more behavioral side effects (irritability, mood changes) compared to Briviact.
Lacosamide (Vimpat)
A sodium channel blocker, also Schedule V. Brand is ~$700–$1,000/month, but generics are available. Well-tolerated by many patients.
Perampanel (Fycompa)
An AMPA receptor antagonist, Schedule III. Brand only at ~$1,200–$1,500/month. Used for both focal and primary generalized seizures.
Cenobamate (Xcopri)
A newer antiepileptic with a dual mechanism of action. Brand only at ~$800–$1,200/month. Approved for focal seizures in adults.
Prefer Briviact? We can find it.
Rifampin
moderateDecreases Briviact levels by about 45%; dose increase up to 100% may be needed
Carbamazepine
moderateBriviact increases the active metabolite (carbamazepine-epoxide); may need to reduce Carbamazepine dose
Phenytoin
moderateBriviact can increase Phenytoin levels; monitor and adjust as needed
Other CNS depressants (benzodiazepines, opioids, alcohol)
moderateadditive sedation
Other antiepileptic drugs metabolized by CYP2C19
moderateBriviact is an effective anticonvulsant for patients with partial-onset seizures, particularly those who have not responded well to or experienced behavioral side effects with Levetiracetam. While the brand-name price is high ($1,500–$2,000/month), the UCB Savings Card can reduce costs to as little as $10 per fill for commercially insured patients.
A generic oral solution became available in early 2026, and generic tablets are anticipated soon, which should significantly lower out-of-pocket costs. If you're having trouble finding Briviact at your pharmacy, use Medfinder to search for pharmacies that have it in stock near you. And always talk to your neurologist before making any changes to your epilepsy medication regimen.
Medfinder Editorial Standards
Our medication guides are researched and written to help patients make informed decisions. All content is reviewed for accuracy and updated regularly. Learn more about our standards